As of May 22
| +0.10 / +0.78%|
The 5 analysts offering 12-month price forecasts for Regulus Therapeutics Inc have a median target of 30.00, with a high estimate of 41.00 and a low estimate of 25.00. The median estimate represents a +133.46% increase from the last price of 12.85.
The current consensus among 6 polled investment analysts is to Buy stock in Regulus Therapeutics Inc. This rating has held steady since May, when it was unchanged from a Move your mouse over past
months for detail
Move your mouse over a quarter or year to see how estimates have changed over time.